Get the Stockscreener App
5.76
1.54%
-0.09
After Hours:
5.77
0.010
+0.17%
Vir Biotechnology Inc stock is traded at $5.76, with a volume of 712.82K.
It is down -1.54% in the last 24 hours and up +9.30% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.85
Open:
$5.79
24h Volume:
712.82K
Relative Volume:
0.55
Market Cap:
$796.25M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.4694
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+4.92%
1M Performance:
+9.30%
6M Performance:
-45.81%
1Y Performance:
-42.97%
1-Day Range:
$5.70
$5.89
1-Week Range:
$5.305
$5.98
52-Week Range:
$4.32
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.76 | 808.69M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology Begins Phase 1 Trial for VIR-5525 - TipRanks
Vir Biotechnology doses first patient in EGFR-targeted cancer trial By Investing.com - Investing.com South Africa
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Yahoo Finance
Vir Biotechnology Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What drives Vir Biotechnology Inc. stock priceUnstoppable investment returns - Autocar Professional
Vir Biotechnology: Hep B And Cancer Projects March On (NASDAQ:VIR) - Seeking Alpha
Have Insiders Sold Vir Biotechnology Shares Recently? - simplywall.st
What analysts say about Vir Biotechnology Inc. stockRapidly expanding wealth - jammulinksnews.com
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
Is Vir Biotechnology Inc. a good long term investmentSuperior investment outcomes - jammulinksnews.com
(VIR) Investment Analysis and Advice - news.stocktradersdaily.com
Vir Biotechnology EVP Eisner sells $57k in stock By Investing.com - Investing.com Canada
Biotech IPO For The Week Ahead - RTTNews
Raymond James Initiates Vir Biotechnology(VIR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Where Vir Biotechnology Stands With Analysts - Benzinga
Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target - MarketScreener
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Unraveling Vir Biotechnology's 10.6% Spike: A Technical Deep Dive - AInvest
Unraveling Vir Biotechnology's 8.8% Surge: A Deep Dive - AInvest
How to Take Advantage of moves in (VIR) - news.stocktradersdaily.com
Vir Biotechnology Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution - simplywall.st
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com UK
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus
Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Eisner Mark | EVP and Chief Medical Officer |
Jul 17 '25 |
Sale |
5.47 |
3,586 |
19,629 |
104,618 |
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):